<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>Basic and Clinical Neuroscience Journal</title>
<title_fa>مجله علوم اعصاب پایه و بالینی</title_fa>
<short_title>BCN</short_title>
<subject>Medical Sciences</subject>
<web_url>http://bcn.iums.ac.ir</web_url>
<journal_hbi_system_id>137</journal_hbi_system_id>
<journal_hbi_system_user>journal137</journal_hbi_system_user>
<journal_id_issn>2008-126X</journal_id_issn>
<journal_id_issn_online>2228-7442</journal_id_issn_online>
<journal_id_pii></journal_id_pii>
<journal_id_doi>10.32598/bcn</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid></journal_id_sid>
<journal_id_nlai></journal_id_nlai>
<journal_id_science></journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1404</year>
	<month>12</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2026</year>
	<month>3</month>
	<day>1</day>
</pubdate>
<volume>17</volume>
<number>2</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>Efficacy of Fluoxetine, Fluvoxamine, and Sertraline in Treating Anxiety, Depression, and Obsessive-compulsive Disorder</title>
	<subject_fa>Cognitive Neuroscience</subject_fa>
	<subject>Cognitive Neuroscience</subject>
	<content_type_fa>Original</content_type_fa>
	<content_type>Original</content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;div style=&quot;text-align: justify;&quot;&gt;&lt;strong&gt;Introduction&lt;/strong&gt;: This study aimed to compare the efficacy of three common selective serotonin reuptake inhibitors (SSRIs)&amp;mdash;fluoxetine, fluvoxamine, and sertraline&amp;mdash;in treating anxiety disorders, major depressive disorder (MDD), and obsessive-compulsive disorder (OCD).&amp;nbsp;&lt;br&gt;
&lt;strong&gt;Methods&lt;/strong&gt;: This eight-week randomized controlled clinical trial included 90 participants who were randomly assigned to receive either fluoxetine (20 mg), fluvoxamine (150 mg), or sertraline (100 mg). Symptom severity was assessed at baseline and after treatment using the Beck anxiety inventory (BAI), the Beck depression inventory-II (BDI-II), and the Yale-Brown obsessive compulsive scale (Y-BOCS).&amp;nbsp;&lt;br&gt;
&lt;strong&gt;Results&lt;/strong&gt;: All three medications significantly reduced symptoms of anxiety, depression, and OCD (P&lt;0.05). However, a one-way ANOVA showed no statistically significant difference among the efficacies of the three drugs in reducing scores on any of the assessment scales.&amp;nbsp;&lt;br&gt;
&lt;strong&gt;Conclusion&lt;/strong&gt;: While fluoxetine, fluvoxamine, and sertraline were all effective, none demonstrated superior efficacy over the others. The choice of medication should therefore be based on considerations, such as side effect profiles, drug interactions, cost, and patient-specific characteristics.&lt;/div&gt;</abstract>
	<keyword_fa></keyword_fa>
	<keyword>Selective serotonin reuptake inhibitors (SSRIs), Fluoxetine, Obsessive-compulsive disorder (OCD), Fluvoxamine, Sertraline, Depression, Anxiety</keyword>
	<start_page>337</start_page>
	<end_page>344</end_page>
	<web_url>http://bcn.iums.ac.ir/browse.php?a_code=A-10-8104-1&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>Mohammad Saeed</first_name>
	<middle_name></middle_name>
	<last_name>Maniati</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>saeedmaniati@gmail.com</email>
	<code>13700319475328460058693</code>
	<orcid>13700319475328460058693</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Neuroscience Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. </affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Reza</first_name>
	<middle_name></middle_name>
	<last_name>Khosrowabadi</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>Reza Khosrowabadi</email>
	<code>13700319475328460058694</code>
	<orcid>13700319475328460058694</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Institute for Cognitive and Brain Sciences, Shahid Beheshti University, Tehran, Iran.</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Jamal</first_name>
	<middle_name></middle_name>
	<last_name>Shams</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>J_shams@yahoo.com</email>
	<code>13700319475328460058695</code>
	<orcid>13700319475328460058695</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Neuroscience Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. </affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
